1
|
Bollati M, Peqini K, Barone L, Natale C, Beeg M, Gobbi M, Diomede L, Trucchi M, de Rosa M, Pellegrino S. Rational Design of a Peptidomimetic Inhibitor of Gelsolin Amyloid Aggregation. Int J Mol Sci 2022; 23:ijms232213973. [PMID: 36430461 PMCID: PMC9698219 DOI: 10.3390/ijms232213973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Revised: 11/08/2022] [Accepted: 11/10/2022] [Indexed: 11/16/2022] Open
Abstract
Gelsolin amyloidosis (AGel) is characterized by multiple systemic and ophthalmic features resulting from pathological tissue deposition of the gelsolin (GSN) protein. To date, no cure is available for the treatment of any form of AGel. More than ten single-point substitutions in the GSN gene are responsible for the occurrence of the disease and, among them, D187N/Y is the most widespread variant. These substitutions undergo an aberrant proteolytic cascade, producing aggregation-prone peptides of 5 and 8 kDa, containing the Gelsolin Amyloidogenic Core, spanning residues 182-192 (GAC182-192). Following a structure-based approach, we designed and synthesized three novel sequence-specific peptidomimetics (LB-5, LB-6, and LB-7) built on a piperidine-pyrrolidine unnatural amino acid. LB-5 and LB-6, but not LB-7, efficiently inhibit the aggregation of the GAC182-192 amyloidogenic peptides at sub-stoichiometric concentrations. These peptidomimetics resulted also effective in vivo, in a C. elegans-based assay, in counteracting the proteotoxicity of aggregated GAC182-192. These data pave the way to a novel pharmacological strategy against AGel and also validate a toolbox exploitable in other amyloidogenic diseases.
Collapse
Affiliation(s)
- Michela Bollati
- Institute of Biophysics, National Research Council (IBF-CNR), c/o Department of Biosciences, University of Milano, Via Celoria 26, 20133 Milano, Italy
| | - Kaliroi Peqini
- Department of Pharmaceutical Science, “A. Marchesini” General and Organic Chemistry Section, University of Milano, Via Venezian 21, 20133 Milano, Italy
| | - Luigi Barone
- Department of Pharmaceutical Science, “A. Marchesini” General and Organic Chemistry Section, University of Milano, Via Venezian 21, 20133 Milano, Italy
| | - Carmina Natale
- Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milano, Italy
| | - Marten Beeg
- Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milano, Italy
| | - Marco Gobbi
- Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milano, Italy
| | - Luisa Diomede
- Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milano, Italy
| | - Michelangelo Trucchi
- Institute of Biophysics, National Research Council (IBF-CNR), c/o Department of Biosciences, University of Milano, Via Celoria 26, 20133 Milano, Italy
| | - Matteo de Rosa
- Institute of Biophysics, National Research Council (IBF-CNR), c/o Department of Biosciences, University of Milano, Via Celoria 26, 20133 Milano, Italy
- Correspondence: (M.d.R.); (S.P.)
| | - Sara Pellegrino
- Department of Pharmaceutical Science, “A. Marchesini” General and Organic Chemistry Section, University of Milano, Via Venezian 21, 20133 Milano, Italy
- Correspondence: (M.d.R.); (S.P.)
| |
Collapse
|
2
|
Bulyáki É, Kun J, Molnár T, Papp A, Micsonai A, Vadászi H, Márialigeti B, Kovács AI, Gellén G, Yamaguchi K, Lin Y, So M, Józsi M, Schlosser G, Lee YH, Liliom K, Goto Y, Kardos J. Pathogenic D76N Variant of β 2-Microglobulin: Synergy of Diverse Effects in Both the Native and Amyloid States. BIOLOGY 2021; 10:biology10111197. [PMID: 34827190 PMCID: PMC8614874 DOI: 10.3390/biology10111197] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Revised: 11/11/2021] [Accepted: 11/11/2021] [Indexed: 01/13/2023]
Abstract
Simple Summary Elevated β2-microglobulin (β2m) serum levels cause serious complications in patients on long-term kidney dialysis by depositing in the form of amyloid fibrils in the osteoarticular system. Recently, a hereditary systemic amyloidosis was discovered, caused by a naturally occurring D76N β2m mutant exhibiting normal serum levels and a distinct, visceral deposition pattern. D76N β2m showed a structure remarkably similar to the wild-type (WT) protein, albeit with decreased thermodynamic stability and increased amyloidogenicity. Despite the extensive research, the molecular bases of the aberrant aggregation of β2m in vivo remains elusive. Here, using a variety of biophysical techniques, we investigated the role of the pathogenic D76N mutation in the amyloid formation of β2m by point mutations affecting the stabilizing ion-pairs of β2m. We found that, relative to WT β2m, the exceptional amyloidogenicity of the pathogenic D76N β2m variant is realized by the synergy of diverse effects of destabilized native structure, higher sensitivity to negatively charged amphiphilic molecules and polyphosphate, more effective fibril nucleation, higher conformational stability of fibrils, and elevated affinity for extracellular matrix proteins. Understanding the underlying molecular mechanisms might help to find target points for effective treatments against diseases associated with the deleterious aggregation of proteins. Abstract β2-microglobulin (β2m), the light chain of the MHC-I complex, is associated with dialysis-related amyloidosis (DRA). Recently, a hereditary systemic amyloidosis was discovered, caused by a naturally occurring D76N β2m variant, which showed a structure remarkably similar to the wild-type (WT) protein, albeit with decreased thermodynamic stability and increased amyloidogenicity. Here, we investigated the role of the D76N mutation in the amyloid formation of β2m by point mutations affecting the Asp76-Lys41 ion-pair of WT β2m and the charge cluster on Asp38. Using a variety of biophysical techniques, we investigated the conformational stability and partial unfolding of the native state of the variants, as well as their amyloidogenic propensity and the stability of amyloid fibrils under various conditions. Furthermore, we studied the intermolecular interactions of WT and mutant proteins with various binding partners that might have in vivo relevance. We found that, relative to WT β2m, the exceptional amyloidogenicity of the pathogenic D76N β2m variant is realized by the deleterious synergy of diverse effects of destabilized native structure, higher sensitivity to negatively charged amphiphilic molecules (e.g., lipids) and polyphosphate, more effective fibril nucleation, higher conformational stability of fibrils, and elevated affinity for extracellular components, including extracellular matrix proteins.
Collapse
Affiliation(s)
- Éva Bulyáki
- ELTE NAP Neuroimmunology Research Group, Department of Biochemistry, Institute of Biology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary; (É.B.); (J.K.); (A.M.); (H.V.)
| | - Judit Kun
- ELTE NAP Neuroimmunology Research Group, Department of Biochemistry, Institute of Biology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary; (É.B.); (J.K.); (A.M.); (H.V.)
| | - Tamás Molnár
- Department of Biochemistry, Institute of Biology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary; (T.M.); (B.M.); (A.I.K.)
| | - Alexandra Papp
- Complement Research Group, Department of Immunology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary; (A.P.); (M.J.)
| | - András Micsonai
- ELTE NAP Neuroimmunology Research Group, Department of Biochemistry, Institute of Biology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary; (É.B.); (J.K.); (A.M.); (H.V.)
| | - Henrietta Vadászi
- ELTE NAP Neuroimmunology Research Group, Department of Biochemistry, Institute of Biology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary; (É.B.); (J.K.); (A.M.); (H.V.)
| | - Borbála Márialigeti
- Department of Biochemistry, Institute of Biology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary; (T.M.); (B.M.); (A.I.K.)
| | - Attila István Kovács
- Department of Biochemistry, Institute of Biology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary; (T.M.); (B.M.); (A.I.K.)
| | - Gabriella Gellén
- Department of Analytical Chemistry, Institute of Chemistry, ELTE Eötvös Loránd University, 1117 Budapest, Hungary; (G.G.); (G.S.)
| | - Keiichi Yamaguchi
- Global Center for Medical Engineering and Informatics, Osaka University, Osaka 565-0871, Japan; (K.Y.); (Y.G.)
| | - Yuxi Lin
- Research Center of Bioconvergence Analysis, Korea Basic Science Institute (KBSI), Ochang 28119, Korea; (Y.L.); (Y.-H.L.)
| | - Masatomo So
- Institute for Protein Research, Osaka University, Osaka 565-0871, Japan; or
| | - Mihály Józsi
- Complement Research Group, Department of Immunology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary; (A.P.); (M.J.)
- MTA-ELTE Complement Research Group, Eötvös Loránd Research Network (ELKH), Department of Immunology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary
| | - Gitta Schlosser
- Department of Analytical Chemistry, Institute of Chemistry, ELTE Eötvös Loránd University, 1117 Budapest, Hungary; (G.G.); (G.S.)
| | - Young-Ho Lee
- Research Center of Bioconvergence Analysis, Korea Basic Science Institute (KBSI), Ochang 28119, Korea; (Y.L.); (Y.-H.L.)
- Bio-Analytical Science, University of Science and Technology (UST), Daejeon 34113, Korea
- Graduate School of Analytical Science and Technology (GRAST), Chungnam National University (CNU), Daejeon 34134, Korea
- Research Headquarters, Korea Brain Research Institute (KBRI), Daegu 41068, Korea
| | - Károly Liliom
- Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University, 1094 Budapest, Hungary;
| | - Yuji Goto
- Global Center for Medical Engineering and Informatics, Osaka University, Osaka 565-0871, Japan; (K.Y.); (Y.G.)
- Institute for Protein Research, Osaka University, Osaka 565-0871, Japan; or
| | - József Kardos
- ELTE NAP Neuroimmunology Research Group, Department of Biochemistry, Institute of Biology, ELTE Eötvös Loránd University, 1117 Budapest, Hungary; (É.B.); (J.K.); (A.M.); (H.V.)
- Correspondence:
| |
Collapse
|